Emil D. Kakkis Sells 11,727 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ultragenyx Pharmaceutical Stock Down 0.5 %

Shares of NASDAQ RARE opened at $42.07 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The company has a market cap of $3.88 billion, a price-to-earnings ratio of -6.50 and a beta of 0.56. The business has a fifty day simple moving average of $47.47 and a 200-day simple moving average of $49.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s quarterly revenue was up 42.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.23) earnings per share. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $33,000. True Wealth Design LLC acquired a new position in Ultragenyx Pharmaceutical during the third quarter valued at $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical during the third quarter valued at $56,000. Wilmington Savings Fund Society FSB purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth about $83,000. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth about $93,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. TD Cowen raised their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $88.46.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.